Molnupiravir: everything you need to know about the new Covid pill
UK approves ‘game-changer’ medication for at-risk patients to take at home
![Covid pill capsules](https://cdn.mos.cms.futurecdn.net/M7mKLfFyQcjtvYw4vpsthN-415-80.png)
The UK has become the first country to approve the use of an oral medication that can be taken at home to treat Covid-19.
Molnupiravir was given the green light today by the UK’s regulatory body for medicines. The pill “will be a game-changer for the most vulnerable and the immunosuppressed”, said Health Secretary Sajid Javid.
Who will get it?
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
![https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516.jpg](https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516-320-80.jpg)
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
The oral antiviral, developed by two US companies – Ridgeback Biotherapeutics and Merck, Sharp & Dohme – has been approved for use by patients with mild to moderate cases of Covid who also present at least one risk factor. Elderly people, diabetics and people with heart disease will be among the first to be offered the treatment.
How does it work?
Molnupiravir works by targeting the enzyme that is responsible for causing the coronavirus to replicate within the body by “introducing errors into its genetic code”, said the BBC. “That should prevent it from multiplying, so keeping virus levels low in the body and reducing the severity of the disease.” Patients can self-administer the medication twice a day, and it is best taken within the first five days of symptoms presenting.
How effective is it?
Clinical trial data showed that the pill “cut the risk of hospitalisation or death by about half” for people at increased risk of developing severe cases of Covid, said the BBC. The Medicines and Healthcare products Regulatory Agency (MHRA) has deemed the treatment both “safe and effective”, with chief executive June Raine describing the medicine as “another therapeutic to add to our armoury against Covid-19”, Sky News reported.
How much does it cost?
The UK has already ordered 480,000 courses of molnupiravir to arrive by the end of the year. Reuters reported that an order for roughly half that amount has also been placed for a similar drug being developed by Pfizer.
The government “has not disclosed” how much the initial Merck, Sharp and Dohme contract has cost, but US authorities struck a deal that worked out at around $700 (£513) per patient, the BBC said. Australia, Singapore and South Korea have also placed orders for the drug.
How long will it take to roll out?
The health secretary said the government is “working at pace” with the NHS to lay out plans to “deploy” the drug to patients “as soon as possible”. He added that it is still “vital” everyone receives a “life-saving Covid-19 vaccine”, as molnupiravir is not a substitute for vaccination.
Penny Ward, a professor in pharmaceutical medicine at King's College London, told the BBC that if trial results are replicated in the UK, “the number of cases requiring hospital admission could be halved and the number of deaths greatly reduced”.
Create an account with the same email registered to your subscription to unlock access.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
-
Red Speedo: a 'darkly comic' doping drama
The Week Recommends Lucas Hnath's play stars Finn Cole as a 'reptilian' swimmer determined to win at all costs
By Irenie Forshaw, The Week UK Published
-
One Aldwych: where London's creative spirit takes centre stage
The Week Recommends This five-star Covent Garden hotel is the epitome of elegant independence
By Julia O'Driscoll, The Week UK Published
-
Charlotte Dujardin and equestrianism's dark side
In the Spotlight Olympic gold medallist and dressage star's suspension over horse whipping brings abuse in horse sports back into the spotlight
By Harriet Marsden, The Week UK Published
-
Brexit, Matt Hancock and black swans: five takeaways from Covid inquiry report
The Explainer UK was 'unprepared' for pandemic and government 'failed' citizens with flawed response, says damning report
By Harriet Marsden, The Week UK Published
-
A 'transformative' gene therapy for haemophilia B
The Explainer Costly treatment that could be 'truly life-changing' for patients with rare blood disorder gets funding boost
By Julia O'Driscoll, The Week UK Published
-
Should masks be here to stay?
Talking Points New York Governor Kathy Hochul proposed a mask ban. Here's why she wants one — and why it may not make sense.
By Anya Jaremko-Greenwold, The Week US Published
-
Covid might be to blame for an uptick in rare cancers
The explainer The virus may be making us more susceptible to certain cancers
By Devika Rao, The Week US Published
-
Long Covid and chronic pain: is it all in the mind?
The Explainer 'Retraining the brain' could offer a solution for some long Covid sufferers
By The Week UK Published
-
Infected blood scandal: will justice be served?
Today's Big Question Government apologises for 'decades-long moral failure' and promises £10bn compensation but true accountability may take far longer
By Harriet Marsden, The Week UK Published
-
Immunotherapy and hay fever
The Explainer Research shows that the treatment could provide significant relief from symptoms for many hay fever sufferers
By Richard Windsor, The Week UK Published
-
Pros and cons of universal health care
Pros and Cons A medical system that serves everyone comes with its own costs, and they're not only financial
By Rebecca Messina, The Week UK Published